<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35000587</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>BMC health services research</Title><ISOAbbreviation>BMC Health Serv Res</ISOAbbreviation></Journal><ArticleTitle>Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer's perspective.</ArticleTitle><Pagination><StartPage>47</StartPage><MedlinePgn>47</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">47</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12913-021-07277-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study is to quantify the health benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer's perspective in Germany.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The analysis is based on a modelling approach using secondary data. The clinical endpoints considered in this analysis are avoided SARS-CoV-2 infections and secondary severe clinical events (death, intensive care unit (ICU) admission, and long COVID syndrome). The study determines the number of self-tests that need to be conducted under a 7-day incidence of 75 per 100,000 population to prevent one infection or severe clinical event. Furthermore, the study calculates the cost of testing per avoided clinical event and quality-adjusted life year (QALY) gained from a consumer perspective.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Disregarding the rate of unreported COVID-19 cases, 4556 self-tests need to be conducted (over 12&#x2009;years) in order to avoid one undesirable event (death, intensive care unit stay, or long COVID syndrome). Ninety percent of infections are not avoided among direct contacts but along the chain of infection. The costs per quality-adjusted life year gained from a consumer's perspective are &#x20ac;5870. This ratio is particularly sensitive to the 7-day incidence, effective reproduction number, and the age of contacts.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The benefits of self-testing in the general population at a 7-day incidence rate of 75 per 100,000 appear to be minor. Nevertheless, cost-effectiveness may still be acceptable in the presence of higher-risk contacts given the low costs of self-test kits in Germany.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gandjour</LastName><ForeName>Afschin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Frankfurt School of Finance &amp; Management, Adickesallee 32-34, 60322, Frankfurt am Main, Germany. a.gandjour@fs.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Health Serv Res</MedlineTA><NlmUniqueID>101088677</NlmUniqueID><ISSNLinking>1472-6963</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085263" MajorTopicYN="Y">Self-Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cost-effectiveness</Keyword><Keyword MajorTopicYN="N">Self-test</Keyword></KeywordList><CoiStatement>The author declares that he has no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>10</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35000587</ArticleId><ArticleId IdType="pmc">PMC8743237</ArticleId><ArticleId IdType="doi">10.1186/s12913-021-07277-4</ArticleId><ArticleId IdType="pii">10.1186/s12913-021-07277-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>U.S. Food &amp; Drug Administration. Coronavirus Disease 2019 Testing Basics. 04/07/2021. https://www.fda.gov/consumers/consumer-updates/coronavirus-disease-2019-testing-basics.</Citation></Reference><Reference><Citation>Paul-Ehrlich-Institut. Mindestkriterien f&#xfc;r SARS-CoV-2 Antigentests im Sinne von &#xa7; 1 Abs. 1 Satz 1 TestVO: Antigenschnelltests. 11.06.2021. https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/mindestkriterien-sars-cov-2-antigentests-01-12-2020.pdf?__blob=publicationFile&amp;v=3.</Citation></Reference><Reference><Citation>Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, Dittrich S, Emperador D, Takwoingi Y, Cunningham J, Beese S, Domen J, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Taylor-Phillips S, Hooft L, Leeflang MM, McInnes MD, Spijker R. Van den Bruel a; Cochrane COVID-19 diagnostic test accuracy group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021;3(3):CD013705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078597</ArticleId><ArticleId IdType="pubmed">33760236</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuit E, Veldhuijzen IK, Venekamp RP, van den Bijllaardt W, Pas SD, Lodder EB, Molenkamp R, GeurtsvanKessel CH, Velzing J, Huisman RC, Brouwer L, Boelsums TL, Sips GJ, Benschop KSM, Hooft L, van de Wijgert JHHM, van den Hof S, Moons KGM. Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. BMJ. 2021;374:n1676. doi: 10.1136/bmj.n1676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1676</ArticleId><ArticleId IdType="pmc">PMC8314145</ArticleId><ArticleId IdType="pubmed">34315770</ArticleId></ArticleIdList></Reference><Reference><Citation>NBC News. Why do Covid rapid tests cost so much even after Biden's push for lower prices? September 12, 2021. https://www.nbcnews.com/health/health-news/why-do-covid-rapid-tests-cost-so-much-even-after-n1278934.</Citation></Reference><Reference><Citation>Robert Koch Institut. Digitales Impfquotenmonitoring zur COVID-19-Impfung. October 15, 2021. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/Impfquoten-Tab.html.</Citation></Reference><Reference><Citation>Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health. 2010;13(1):3&#x2013;7. doi: 10.1111/j.1524-4733.2009.00663.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-4733.2009.00663.x</ArticleId><ArticleId IdType="pubmed">19874571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuniya T, Inaba H. Possible effects of mixed prevention strategy for COVID-19 epidemic: massive testing, quarantine and social distancing. AIMS Public Health. 2020;7(3):490&#x2013;503. doi: 10.3934/publichealth.2020040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/publichealth.2020040</ArticleId><ArticleId IdType="pmc">PMC7505788</ArticleId><ArticleId IdType="pubmed">32968673</ArticleId></ArticleIdList></Reference><Reference><Citation>Forde JE, Ciupe SM. Quantification of the tradeoff between test sensitivity and test frequency in a COVID-19 epidemic-a multi-scale modeling approach. Viruses. 2021;13(3):457. doi: 10.3390/v13030457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030457</ArticleId><ArticleId IdType="pmc">PMC7999334</ArticleId><ArticleId IdType="pubmed">33799660</ArticleId></ArticleIdList></Reference><Reference><Citation>Odagaki T. Estimation of the onset rate and the number of asymptomatic patients of COVID-19 from the proportion of untraceable patients. medRxiv. 2021;07(28):21261241.</Citation></Reference><Reference><Citation>S&#xfc;ddeutsche Zeitung. Bessere &#xdc;berlebenschancen f&#xfc;r Covid-Intensivpatienten. March 28, 2021. https://www.sueddeutsche.de/gesundheit/covid-coronavirus-intensivstationen-sterblichkeit-letalitaet-maenner-frauen-1.5248161.</Citation></Reference><Reference><Citation>Robert Koch Institut. W&#xf6;chentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19). October 21, 2021. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2021-10-21.pdf?__blob=publicationFile</Citation></Reference><Reference><Citation>Robert Koch Institut. COVID-19-F&#xe4;lle nach Meldewoche und Geschlecht sowie Anteile mit f&#xfc;r COVID-19 relevanten Symptomen, Anteile Hospitalisierter/Verstorbener und Altersmittelwert/&#x2212;median. October 21, 2021. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/Klinische_Aspekte.html.</Citation></Reference><Reference><Citation>Bundesgesundheitsministerium. Online-Ratgeber Krankenversicherung: Zuzahlung. March 26, 2021. https://www.bundesgesundheitsministerium.de/zuzahlung-krankenversicherung.html?limit=all.</Citation></Reference><Reference><Citation>Robert Koch Institut. T&#xe4;glicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19). 2021.&#xa0;https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Sept_2021/2021-09-17-de.pdf?__blob=publicationFile.</Citation></Reference><Reference><Citation>Neuhauser H, Buttmann-Schweiger N, Ellert U, Fiebig J, H&#xf6;vener C, Offergeld R, Pr&#xfc;tz F, Sarganas G, Schaade L, Schaffrath Rosario A, Thamm R, Zimmermann M, Poethko-M&#xfc;ller C. Seroepidemiologische Studien zu SARS-CoV-2 in Stichproben der Allgemeinbev&#xf6;lkerung und bei Blutspenderinnen und Blutspendern in Deutschland &#x2013; Ergebnisse bis August 2021. Epid Bull. 2021;37:3&#x2013;12.</Citation></Reference><Reference><Citation>Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579. doi: 10.1136/bmj.n579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n579</ArticleId><ArticleId IdType="pmc">PMC7941603</ArticleId><ArticleId IdType="pubmed">33687922</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimpfl T, S&#xf6;nksen J, Bechmann I, Grammig J. Estimation of the SARS-CoV-2 infection fatality rate in Germany. medRxiv. 2021;01.26:21250507.</Citation></Reference><Reference><Citation>Robert Koch Institut. T&#xe4;glicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19). 2020.&#xa0;https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Dez_2020/2020-12-29-de.pdf?__blob=publicationFile.</Citation></Reference><Reference><Citation>Robert Koch Institut. W&#xf6;chentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019
(COVID-19). 2021.&#xa0;https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2021-10-14.pdf?__blob=publicationFile.</Citation></Reference><Reference><Citation>Federal Office of Statistics . Allgemeine Sterbetafel 2016/2018. Wiesbaden: Federal Office of Statistics; 2019.</Citation></Reference><Reference><Citation>Grochtdreis T, Dams J, K&#xf6;nig HH, Konnopka A. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ. 2019;20(6):933&#x2013;944. doi: 10.1007/s10198-019-01054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10198-019-01054-1</ArticleId><ArticleId IdType="pubmed">31030292</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti J, Hall P, Hamilton P, Lamb S, McCabe C, Lall R, Darbyshire J, Young D, Hulme C. One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): secondary analysis of a randomised controlled trial. J Intensive Care. 2016;4:56. doi: 10.1186/s40560-016-0178-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-016-0178-8</ArticleId><ArticleId IdType="pmc">PMC4982209</ArticleId><ArticleId IdType="pubmed">27525106</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen FH, Flaatten H, Klepstad P, Romild U, Kv&#xe5;le R. Long-term survival and quality of life after intensive care for patients 80 years of age or older. Ann Intensive Care. 2015;5(1):53. doi: 10.1186/s13613-015-0053-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-015-0053-0</ArticleId><ArticleId IdType="pmc">PMC4456598</ArticleId><ArticleId IdType="pubmed">26055187</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandjour A. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. Q Rev Econ Finance. 2020. 10.1016/j.qref.2020.10.007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554483</ArticleId><ArticleId IdType="pubmed">33071532</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of National Statistics. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 20212021. September 16, 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021.</Citation></Reference><Reference><Citation>Cochrane M, Mitchell E, Hollingworth W, Crawley E, Tr&#xe9;pel D. Cost-effectiveness of interventions for chronic fatigue syndrome or Myalgic encephalomyelitis: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2021;19(4):473&#x2013;486. doi: 10.1007/s40258-021-00635-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40258-021-00635-7</ArticleId><ArticleId IdType="pmc">PMC7917957</ArticleId><ArticleId IdType="pubmed">33646528</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieg SJ, Schnur JJ, Miranda ML, Pfrender ME, Chawla NV. Symptomatic, Presymptomatic, and Asymptomatic Transmission of SARS-CoV-2. medRxiv. 2021;07(08):21259871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358125</ArticleId><ArticleId IdType="pubmed">35848117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang M, Xin H, Yuan J, Ali ST, Liang Z, Zhang J, Hu T, Lau EHY, Zhang Y, Zhang M, Cowling BJ, Li Y, Wu P. Transmission dynamics and epidemiological characteristics of Delta variant infections in China. medRxiv. 2021;08(12):21261991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8915401</ArticleId><ArticleId IdType="pubmed">35272744</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert Koch Institut. Informationen zur Ausweisung internationaler Risikogebiete durch das Ausw&#xe4;rtige Amt, BMG und BMI. Stand: 2021.&#xa0;https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Risikogebiete_neu.html.</Citation></Reference><Reference><Citation>Federal Office of Statistics. Fachserie 15 Reihe 1, LWR 2019. Laufende Wirtschaftsrechnungen: Einkommen, Einnahmen und Ausgaben privater Haushalte. Statistisches Bundesamt (Destatis). 2020.</Citation></Reference><Reference><Citation>Robert Koch Institut. Tabellen zu Testzahlen, Testkapazit&#xe4;ten und Probenr&#xfc;ckstau pro Woche. Stand: 2021.&#xa0;https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/Testzahlen-gesamt.html.</Citation></Reference><Reference><Citation>Zeit. F&#xfc;nf vor acht / Betrug bei Corona-Testungen. 02.06.2021. https://www.zeit.de/wirtschaft/2021-06/betrug-corona-testungen-testzentren-schnelltest-pandemie.</Citation></Reference><Reference><Citation>Robert Koch Institut. Nowcasting und R-Sch&#xe4;tzung: Sch&#xe4;tzung der aktuellen Entwicklung der SARS-CoV-2-Epidemie in Deutschland. Stand: 2021.&#xa0;https://github.com/robert-koch-institut/SARS-CoV-2-Nowcasting_und_-R-Schaetzung/blob/main/Nowcast_R_aktuell.csv.</Citation></Reference><Reference><Citation>Bundesgesundheitsministerium. Fragen und Antworten zu Schnell- und Selbsttests zum Nachweis von SARS-CoV-2. 10. M&#xe4;rz. 2021; https://www.bundesgesundheitsministerium.de/coronatest/faq-schnelltests.html?fbclid=iwar1lu5u9z9blu3tcuq1ynucqu835dzf1w820xn1nvsg5.</Citation></Reference><Reference><Citation>Wong TL, Weitzer DJ. Long COVID and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas) 2021;57(5):418. doi: 10.3390/medicina57050418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorji H, Arnoldini M, Jenny DF, Hardt W-D, Jenny P. Smart Investment of Virus RNA Testing Resources to Enhance Covid-19 Mitigation. medRxiv. 2020;11(30):20239566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631684</ArticleId><ArticleId IdType="pubmed">34847176</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>